Plan your SSC preparation with expert-designed Oswaal Books featuring solved papers, question banks and exam-focused practice to boost accuracy and confidence.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS) backing off a plan to offer a knockoff Wegovy pill for as little as $49 ...

On Thursday, Hims & Hers Health Inc. (NYSE: HIMS) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ...

Turning a $100,000 portfolio into $1 million in 10 years requires a compound annual growth rate (CAGR) of roughly 26%. Your growth stock picks should be capable of consistently growing revenue, ...

Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 ...

Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. In April 2025, the U.S. Food and Drug Administration ...

Forbes contributors publish independent expert analyses and insights. Wayne Winegarden covers the economic impacts of regulatory policies The new class of GLP-1 medicines exemplifies both the ...

Westlake Corporation WLK announced that it will acquire the global compounding solutions businesses of the ACI/Perplastic Group (“ACI”). Portugal-based ACI is a leading manufacturer of specialty ...

The FDA has received hundreds of adverse event reports after people used compounded GLP-1 drugs for weight loss. Compounded GLP-1 drugs aren’t reviewed by the FDA for safety or effectiveness. The FDA ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests there is ...